Nucleic acid-based therapeutics represent an emerging class of drugs with the potential to treat a wide range of central nervous system disorders. Currently, several nucleic acid-based therapeutics have shown potential in preclinical trials for the treatment of psychiatric disorders, holding promise for the development of innovative therapeutics for psychiatric disorders.

Ace Therapeutics, a preclinical CRO specializing in psychiatric disorders, offers specialized services to facilitate the development of nucleic acid-based drug discovery for use in psychiatric disorders. Our focus is to provide comprehensive solutions to support the early stages of nucleic acid drug discovery, particularly in psychiatric disorders. With advanced analytical techniques, early-stage drug development experience, and high-quality animal models, we will help you make breakthroughs in the development of innovative therapies for psychiatric disorders.

Fig. 1 Using TDNs in combination with miRNAs to treat depression. (Luo, Y.; et al., 2023)

Our Nucleic Acid-Based Antipsychotic Drug Development Services

Ace Therapeutics leverages our extensive experience in early drug discovery and preclinical testing services to provide clients with customized, one-stop solutions that facilitate advancement in nucleic acid drug development. The specific services we offer are outlined below:

• Target identification and validation

We utilize bioinformatics tools and high-throughput screening to comprehensively screen and validate specific genes associated with psychiatric disorders, genes related to neurotransmitter synthesis, release, and reuptake, genes regulating neural pathways and, genes related to neuroinflammation. We achieve precision targeting by designing interventional drugs against these genes.

• Oligonucleotide design and optimization

We use computer-aided design tools to design nucleic acid drugs against specific targets and optimize their structures. Our drug design services encompass a comprehensive range of options, including, but not limited to, ASOs, short interfering RNAs (siRNAs), therapeutic mRNAs, gene therapy constructs, RNA-encoded enzymes, and more.

• Delivery system development

We help you choose the right delivery system for optimal drug delivery through chemical modification and nanotechnology.

• Preclinical efficacy and safety evaluation

We employ in vitro cellular models and in vivo animal models to comprehensively analyze and evaluate the efficacy, safety, and pharmacokinetics of potential antipsychotic drugs to identify the most promising candidates for your consideration.

Key Therapeutic Areas

• Depression
• Anxiety
• Schizophrenia
• Autism spectrum disorders
• Post-traumatic stress disorder
• Bipolar disorder
• Borderline personality disorder
• Anorexia nervosa
• Bulimia nervosa
• Sleep-wake disorders
• Obsessive-compulsive disorder
• Attention deficit hyperactivity disorder
• Addiction

Our Technologies and Capabilities

Our professional research team and state-of-the-art experimental platform allow us to provide high-quality R&D services and collaborate with you on the development of nucleic acid-based antipsychotic drugs.

• Behavioral and in vivo testing
• Biomarker development
• Electroencephalography
• Electrophysiological analysis
• Neuroimaging
• In vivo efficacy testing
• Molecular biology
• Immunological and histochemical analysis

Ace Therapeutics is dedicated to providing comprehensive nucleic acid-based antipsychotic drug development services to our clients. Our dedicated team and advanced technology platforms ensure the highest standards in every aspect of drug design and preclinical evaluation, helping clients accelerate their drug development process. Please contact us for more details and we will be happy to assist you.

Reference

1. Luo, Y.; et al. DNA Tetrahedra-Based Delivery of MicroRNA-22 to Reduce Depressive Symptoms in Mice. ACS Applied Materials & Interfaces. 15.25 (2023): 29813-29826.